Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19
Samuel K. Lai, Morgan D. McSweeney, Raymond J. Pickles
Journal of Controlled Release (2020) Vol. 329, pp. 87-95
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Immunopathology of RSV: An Updated Review
Harrison C. Bergeron, Ralph A. Tripp
Viruses (2021) Vol. 13, Iss. 12, pp. 2478-2478
Open Access | Times Cited: 65
Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections
Morgan D. McSweeney, Sarhad Alnajjar, Alison Schaefer, et al.
Advanced Science (2024) Vol. 11, Iss. 12
Open Access | Times Cited: 7
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers
Thomas R. Moench, Lakshmi Botta, Brian T. Farrer, et al.
EBioMedicine (2025) Vol. 113, pp. 105582-105582
Closed Access
Novel formulations and drug delivery systems to administer biological solids
Yajie Zhang, Daniel A. Davis, Khaled AboulFotouh, et al.
Advanced Drug Delivery Reviews (2021) Vol. 172, pp. 183-210
Closed Access | Times Cited: 35
Engineering a “muco‐trapping” ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19
Karthik Tiruthani, Carlos Cruz‐Teran, Jasper Fuk‐Woo Chan, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 3
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
José María Soberanes Diez, Carolina S. Romero, Maria Cristina Cruz, et al.
The Journal of Infectious Diseases (2021) Vol. 225, Iss. 6, pp. 938-946
Open Access | Times Cited: 28
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
Olga Minenkova, Daniela Santapaola, Ferdinando Maria Milazzo, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1979-1993
Open Access | Times Cited: 18
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
Tharmala Tharmalingam, Xiaobing Han, Ashley Wozniak, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 2
Open Access | Times Cited: 23
A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters
Sonali Chaturvedi, Nathan Beutler, Gustavo Vasen, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 39
Open Access | Times Cited: 15
Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody
Vishakha Singh, Mandar Bhutkar, Shweta Choudhary, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 734, pp. 150746-150746
Closed Access | Times Cited: 2
Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
Morgan D. McSweeney, Ian E. Stewart, Zach Richardson, et al.
Bioengineering & Translational Medicine (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 14
A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies
Elif Seymour, M. Selim Ünlü, John H. Connor
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates
Paule Hermet, Benoît Delache, Cécile Herate, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011532-e1011532
Open Access | Times Cited: 7
A novel nanobody broadly neutralizes SARS‐CoV‐2 via induction of spike trimer dimers conformation
Yang Yang, Junfang Zhang, Shengnan Zhang, et al.
Exploration (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 7
Enhancing affinity of neutralizing SARS-CoV-2 nanobody through facile structure-guided mutations in CDRs
Vishakha Singh, Mandar Bhutkar, Shweta Choudhary, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Upregulation of key factors of viral entry of corona‐ and influenza viruses upon TLR3‐signaling in cells from the respiratory tract and clinical treatment options by 1,8‐Cineol
Leonie Hose, Matthias Schürmann, Holger Sudhoff
Phytotherapy Research (2024) Vol. 38, Iss. 9, pp. 4453-4466
Open Access | Times Cited: 1
Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant
Vishakha Singh, Shweta Choudhary, Mandar Bhutkar, et al.
International Journal of Biological Macromolecules (2024) Vol. 290, pp. 138751-138751
Closed Access | Times Cited: 1
Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
Jacek Plichta, Piotr Kuna, Michał Panek
COVID (2022) Vol. 2, Iss. 5, pp. 599-620
Open Access | Times Cited: 9
Inhalable antibodies for the treatment of COVID-19
Zhenlin Yang, Cheng Li, Yuanlin Song, et al.
The Innovation (2022) Vol. 3, Iss. 6, pp. 100328-100328
Open Access | Times Cited: 9
Antibody protection from SARS-CoV-2 respiratory tract exposure and infection
Alex Chen, Timothy Wessler, M. Gregory Forest
Journal of Theoretical Biology (2022) Vol. 557, pp. 111334-111334
Open Access | Times Cited: 9
Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 supports its development as a potent, dose-saving inhaled therapy for COVID-19
Morgan D. McSweeney, Ian E. Stewart, Zach Richardson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
Thomas R. Moench, Lakshmi Botta, Brian T. Farrer, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19
Homa Nath Sharma, Charity O. D. Latimore, Qiana L. Matthews
Pathogens (2021) Vol. 10, Iss. 9, pp. 1218-1218
Open Access | Times Cited: 8
Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation
Peng Lü, Faith Leslie, Han Wang, et al.
Journal of Controlled Release (2023) Vol. 364, pp. 1-11
Open Access | Times Cited: 2
Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying
Haiyue Xu, Sawittree Sahakijpijarn, Chaeho Moon, et al.
International Journal of Pharmaceutics (2024) Vol. 662, pp. 124511-124511
Closed Access
Page 1 - Next Page

Scroll to top